product name Pioglitazone
Description: Pioglitazone is a potent and selective peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, which is used to treat diabetes. Pioglitazone Hydrochloride is a thiazolidinedione compound described to produce antiinflammatory and antiarteriosclerotic effects. Pioglitazone is demonstrated to prevent L-NAME-induced coronary inflammation and arteriosclerosis.
References: Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51; Circulation. 2002 Dec 10;106(24):3126-32.
356.44
Formula
C19H20N2O3S
CAS No.
111025-46-8
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 15 mg/mL (42.1 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
other peoduct :
| In Vitro |
In vitro activity: Pioglitazone significantly attenuates left ventricular (LV) cavity dilatation and dysfunction by echocardiography as well as LV end-diastolic pressure in mice with extensive anterior myocardial infarction. Pioglitazone partially normalizes LV dP/dt(max) and dP/dt(min), indices of LV contractile function, which are significantly reduced in MI mice. Pioglitazone results in a reduced activation of microglia, reduced induction of iNOS-positive cells and less glial fibrillary acidic protein positive cells in both striatum and substantia nigra pars compacta of MPTP mouse model of Parkinsons disease. Pioglitazone almost completely blocks staining of TH-positive neurons for nitrotyrosine, a marker of NO-mediated cell damage. Pioglitazone (approximately 20 mg/kg/day) attenuates the MPTP-induced glial activation and prevents the dopaminergic cell loss in the substantia nigra pars compacta (SNpc) in MPTP mouse model of Parkinsons disease. Pioglitazone results in a reduction in the number of activated microglia and reactive astrocytes in the hippocampus and cortex of 10-month-old APPV717I transgenic mice. Pioglitazone treatment reduces the expression of the proinflammatory enzymes cyclooxygenase 2 (COX2) and inducible nitric oxide synthase (iNOS). Pioglitazone decreases beta-secretase-1 (BACE1) mRNA and protein levels, and also a 27% reduction in the levels of soluble Abeta1-42 peptide. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51; Circulation. 2002 Dec 10;106(24):3126-32. |
